Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J. Valentim
Costs of HER 2 Negative, Hormonal Receptor Positive, Metastatic Breast Cancer (MBC-HR+) Treated With Everolimus (EVE) + Exemestane (EXE) in the Brazilian Private System (BPS): A Real World (RW) and Published Literature Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Abiotic Modulation of Spartina Maritima Photobiology in Different Latitudinal Populations
Estuarine, Coastal and Shelf Science
Oceanography
Aquatic Science
Related publications
Correction 2: Everolimus (EVE) and Exemestane (EXE) in Patients With Advanced Breast Cancer Aged ≥ 65 Years: New Lessons for Clinical Practice From the EVA Study
Oncotarget
Oncology
Correction: Everolimus (EVE) and Exemestane (EXE) in Patients With Advanced Breast Cancer Aged ≥ 65 Years: New Lessons for Clinical Practice From the EVA Study
Oncotarget
Oncology
Real-World Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
Scientific Reports
Multidisciplinary
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Geburtshilfe und Frauenheilkunde
Gynecology
Midwifery
Maternity
Obstetrics
Exemestane as Third and Fourth Line Hormonal Therapy for Metastatic Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Pcn27 - The Real-World Cost and Effectiveness of Everolimus in Metastatic Breast Cancer in the Czech Republic
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Investigational New Drugs
Oncology
Pharmacology
Pcn75 - Budget Impact Model of Subcutaneous Trastuzumab Compared With Intravenous Trastuzumab on the Treatment of Her-2 Positive Breast Cancer in the Brazilian Private Healthcare System
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
